Savara, Inc. (SVRA)

NASDAQ: SVRA · Delayed Price · USD
1.30
-0.02 (-1.52%)
At close: May 26, 2022 3:59 PM
1.28
-0.02 (-1.54%)
After-hours:May 26, 2022 4:00 PM EDT

Company Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.

Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis.

The company is headquartered in Austin, Texas.

Savara, Inc.
Savara Logo
CountryUnited States
IndustryBiotechnology
SectorHealth Care
Employees22
CEORobert Neville

Contact Details

Address:
900 S Capital of Texas Hwy
West Lake Hills, Texas 78746-5469
United States
Phone512 614 1848
Websitesavarapharma.com

Stock Details

Ticker SymbolSVRA
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001160308

Key Executives

NamePosition
Matthew PaulsChairman and Chief Executive Officer
David L. Lowrance CPAChief Financial Officer and Secretary
Dr. Badrul A. Chowdhury M.D., Ph.D.Chief Medical Officer
Kate McCabeSenior Vice President of Legal Affairs
Anne EricksonSenior Vice President and Chief of Staff
Dr. Dhaval Desai M.D.Senior Vice President and Head of Clinical Development
Brian MaurerHead of Clinical Operations
Charles LaPreeSenior Vice President of Global Regulatory Affairs and Quality Assurance
Dr. Peter Clarke Ph.D.Executive Vice President of Global Technical Operations

Latest SEC Filings

DateTypeTitle
May 11, 202210-QQuarterly report [Sections 13 or 15(d)]
Apr 22, 20228-KCurrent report
Apr 19, 2022DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 19, 2022DEF 14AOther definitive proxy statements
Mar 30, 2022S-8Securities to be offered to employees in employee benefit plans
Mar 30, 202210-KAnnual report [Section 13 and 15(d), not S-K Item 405]
Feb 14, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Feb 14, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Feb 10, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Jan 13, 20228-KCurrent report
View All SEC Filings